HC Wainwright Predicts Humacyte’s Q4 Earnings (NASDAQ:HUMA)

Humacyte, Inc. (NASDAQ:HUMA) – HC Wainwright issued their Q4 2027 earnings per share estimates for Humacyte in a note issued to investors on Thursday, May 14th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.05) for the quarter. The consensus estimate for Humacyte’s current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Humacyte’s FY2029 earnings at $0.06 EPS and FY2030 earnings at $0.34 EPS.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The business had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $1.46 million.

HUMA has been the topic of several other research reports. Wall Street Zen upgraded Humacyte from a “strong sell” rating to a “sell” rating in a report on Saturday. BTIG Research cut their price objective on Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Benchmark cut their price objective on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 21st. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a report on Tuesday, April 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a report on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $7.57.

Humacyte Stock Performance

NASDAQ:HUMA opened at $0.93 on Monday. Humacyte has a fifty-two week low of $0.55 and a fifty-two week high of $2.93. The company has a debt-to-equity ratio of 5.46, a current ratio of 3.93 and a quick ratio of 3.32. The stock has a market capitalization of $206.50 million, a PE ratio of -1.63 and a beta of 2.31. The business’s 50-day simple moving average is $0.85 and its 200-day simple moving average is $1.06.

Institutional Investors Weigh In On Humacyte

Several large investors have recently made changes to their positions in the stock. Concurrent Investment Advisors LLC boosted its holdings in shares of Humacyte by 16.6% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 59,615 shares of the company’s stock valued at $104,000 after buying an additional 8,500 shares during the last quarter. SG Americas Securities LLC increased its holdings in Humacyte by 50.3% during the fourth quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock worth $33,000 after buying an additional 11,411 shares during the last quarter. Independent Advisor Alliance increased its holdings in Humacyte by 49.4% during the third quarter. Independent Advisor Alliance now owns 36,240 shares of the company’s stock worth $63,000 after buying an additional 11,991 shares during the last quarter. Prudential Financial Inc. acquired a new position in Humacyte during the second quarter worth $28,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in Humacyte by 21.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock worth $73,000 after buying an additional 13,175 shares during the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.